Calreticulin and JAK2 Exon 12 Mutation Screening in Patients with Myeloproliferative Neoplasms’ in Jeddah Region, Saudi Arabia
Heba Alkhatabi, Heyam Abdulqayoom, Raed Alserihi, Raed Felimban, Aisha Elaimi, Zinab Allala, Afaf Magboli, Salem Bahashwan, Hashem Alsalmi, Abdulelah Shihah, Adel Abuzenadah & Elrashed B. Yasin · Journal of Pharmaceutical Research International · 2021
Background: The JAK2 V617F mutation’s discovery has largely facilitated the comprehension of the myeloproliferative neoplasms’(MPNs) pathogenesis. In recent times, calreticulin (CALR) mutations have been detected in patients with JAK2V617F negative primary myelofibrosis (PMF), an...
Open access
Research Article
10.9734/jpri/2021/v33i47A33029